Endpoints News

Endpoints News Endpoints News is an online news outlet that reports on the global biopharmaceutical industry, including pharmaceutical companies, biotechnology firms, regulatory agencies, and research institutions. The outlet provides timely reporting on clinical trials, mergers and acquisitions, regulatory decisions, and industry strategy, publishing newsletters and articles aimed at professionals and observers in life sciences, healthcare investment, and policy. Endpoints News is noted for its focus on insider developments within companies such as Pfizer, Moderna, Roche, AstraZeneca, and Novartis and interactions with regulators like the Food and Drug Administration, European Medicines Agency, and China National Medical Products Administration.

Overview

Endpoints News covers developments across the biotechnology and pharmaceutical sectors, focusing on entities such as GSK, Johnson & Johnson, Merck & Co., Eli Lilly and Company, Sanofi, and emerging companies like CRISPR Therapeutics, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, BioNTech, and Illumina. The site reports on clinical-stage programs, business transactions involving firms like Amgen, Bristol-Myers Squibb, Takeda Pharmaceutical Company, and Bayer, and scientific milestones associated with institutions such as Massachusetts Institute of Technology, Harvard Medical School, Stanford University School of Medicine, Johns Hopkins University, and University of Pennsylvania. Coverage often intersects with regulatory rulings from agencies including National Institutes of Health, Centers for Medicare & Medicaid Services, European Commission, and policy discussions involving lawmakers in United States Congress and international forums like the World Health Organization.

History

Founded in 2017 by journalists with backgrounds covering biotech and pharma, the outlet emerged during a period of intensified public and investor interest in biotechnology driven by companies such as Moderna and BioNTech and scientific advances like mRNA technology and gene editing exemplified by CRISPR-Cas9 research teams at institutions including Broad Institute and University of California, Berkeley. Early reporting tracked merger talks and licensing deals reminiscent of transactions between AbbVie and Allergan and acquisition strategies seen in the buyouts of Celgene by Bristol-Myers Squibb and Medivation by Pfizer. The newsroom expanded as high-profile events—such as vaccine development collaborations among Pfizer and BioNTech, and emergency authorizations by Food and Drug Administration—drove readership interested in clinical trial readouts and corporate maneuvering.

Coverage and Content Focus

The publication emphasizes scoops, deal coverage, trial outcomes, executive hires and departures, and analysis of regulatory decisions. It routinely reports on clinical trial phases involving sponsors like Gilead Sciences, Astellas Pharma, Otsuka Pharmaceutical, Mallinckrodt Pharmaceuticals, and biotech startups funded by investors such as Sequoia Capital, Third Rock Ventures, and ARCH Venture Partners. Scientific content often references studies published in outlets like The New England Journal of Medicine, Nature, Science (journal), and Cell (journal), and highlights translational research from centers such as Dana-Farber Cancer Institute, Salk Institute, and Cleveland Clinic. Business coverage spans licensing agreements similar to deals between Roche and Spark Therapeutics, venture rounds reminiscent of financing for Illumina Ventures portfolio companies, and IPOs on exchanges like Nasdaq and New York Stock Exchange.

Editorial Staff and Ownership

The editorial team consists of reporters, editors, and newsletter writers with prior experience at outlets including STAT (healthcare)],] The Wall Street Journal, Financial Times, Bloomberg News, Reuters, The Boston Globe, Nature (journal), and The New York Times. Key figures have covered corporate affairs at companies like Pfizer and regulatory beats involving the Food and Drug Administration and European Medicines Agency. Ownership is private and has included investors and founders with media and life sciences backgrounds; governance and financial relationships are occasionally disclosed in masthead notes when relevant to editorial coverage, particularly in situations where ties to firms such as Seagen or Alnylam Pharmaceuticals could present perceived conflicts.

Audience and Reception

The audience comprises biotechnology executives, pharmaceutical researchers, venture capitalists, policy analysts, healthcare attorneys, and institutional investors monitoring companies such as BlackRock, Vanguard, Goldman Sachs, and J.P. Morgan. Professionals affiliated with hospitals and universities—Mayo Clinic, Memorial Sloan Kettering Cancer Center, Cedars-Sinai Medical Center—and employees of biotech hubs like Kendall Square and Boston (Massachusetts) follow the outlet for deal intelligence and trial updates. Industry trade groups including PhRMA and advocacy organizations like BIO (trade association) and patient groups frequently react to stories, and the publication’s newsletters are cited by analysts on platforms such as Bloomberg Television, CNBC, and Financial Times.

Controversies and Criticism

Like many specialized outlets, the publication has faced scrutiny over sourcing practices, anonymous sourcing policies, and potential conflicts involving ownership or compensation when reporting on companies such as Moderna, Pfizer, Gilead Sciences, and Regeneron Pharmaceuticals. Critics from journalists’ unions, media watchdogs, and commentators at outlets including Columbia Journalism Review, Poynter Institute, and The Washington Post have questioned transparency in certain pieces and called for clearer disclosures when staff have personal or financial ties to subjects. Legal disputes and threatened litigation have occasionally arisen from investigative stories alleging undisclosed business dealings or executive misconduct tied to firms like Theranos-related entities or startups with high-profile founders from Google and Amazon.